Author Affiliations: Departments of Dermatology and Child Health, University of Missouri, Columbia.
In 2008, systemic administration of β-adrenergic blockers was found to dramatically improve hemangiomas of infancy (HOI).1 This watershed event of a new use for an established drug in the pediatric dermatologic treatment of HOI changed treatment protocols around the world.2 Concern has been raise about possible overtreatment of HOI now, compared with prior to 2008, but the change in treatment of HOI is more likely owing to the lack of low-risk interventions prior to 2008 than to current overtreatment.
Dyer JA. Propranolol to Treat Hemangiomas of Infancy: Safety and Side Effect Recognition: Comment on “Retrospective Review of Adverse Effects from Propranolol in Infants”. JAMA Dermatol. 2013;149(4):481–504. doi:10.1001/jamadermatol.2013.3
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: